Endpoint choice for inclusion body myositis: a step too far?
Schmidt J
The Lancet. Neurology, 2019, 18, 9, p 807
The Lancet. Neurology, 2019, 18, 9, p 807
|
Voir aussi
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Hanna MG, Badrising UA, Benveniste O, et al.
The Lancet. Neurology, 2019, 18, 9, p 834
Myosites : les résultats de l’essai RESILIENT sont parus !
Marion S
2019